In vitro and in vivo activity of Ribavirin against Andes virus infection

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Safronetz, David ^a   Haddock, Elaine ^a   Feldmann, Friederike ^a   Ebihara, Hideki ^a   Feldmann, Heinz ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RIBAVIRIN; VIRUS PROTEIN; VIRUS RNA; ANTIVIRUS AGENT;

ANDES VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INHIBITION; FEMALE; HANTAVIRUS; HANTAVIRUS PULMONARY SYNDROME; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; POST EXPOSURE PROPHYLAXIS; TREATMENT OUTCOME; VERO CELL; ANIMAL; CERCOPITHECUS; DRUG EFFECT; HAMSTER; HANTAVIRUS INFECTION; LUNG; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHYSIOLOGY; PROTEIN SYNTHESIS; SYRIAN HAMSTER; VIROLOGY; VIRUS REPLICATION;

ANDES VIRUS; CRICETINAE; HANTAAN VIRUS; HANTAVIRUS; RODENTIA;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; CRICETINAE; HANTAVIRUS; HANTAVIRUS INFECTIONS; LUNG; MESOCRICETUS; PROTEIN BIOSYNTHESIS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VERO CELLS; VIRUS REPLICATION;

EID: 80051519131     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023560     Document Type: Article

References (31)

1. Nichol ST, Elliott RM, Goldbach R, Plyusnin A, Schmaljohn CS, et al. (2005) Bunyaviridae. In: Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA, editors. Virus Taxonomy, VIIIth Report of the International Committee on Taxonomy of Viruses London Elsevier Academic Press pp. 695-716.
2. Jonsson CB, Figueiredo LTM, Vapalahti O, (2010) A global perspective on hantavirus ecology, epidemiology and disease. Clin Microbiol Rev 23: 412-441.
3. Martinez VP, Bellomo C, San Juan J, Pinna D, Forlenza R, et al. (2005) Person-to-person transmission of Andes virus. Emerg Infect Dis 11: 1848-1853.
4. Padula PJ, Edelstein A, Miquel SD, Lopez NM, Rossi CM, et al. (1998) Hantavirus pulmonary syndrome outbreak in Argentina: molecular evidence for person-to-person transmission of Andes virus. Virol 241: 323-330.
5. Schmaljohn C, (2009) Vaccines for hantaviruses. Vaccine 27: D61-D64.
6. Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, et al. (2007) In vitro and in vivo activities of T-705 against Arenavirus and Bunyavirus infections. Antimicrob Agents Chemother 51: 3168-3176.
7. Kirsi JJ, North JA, McKernan PA, Murphy BK, Canonico PG, et al. (1983) Broad-spectrum antiviral activity of 2-β-Dribofuranosylselenazole-4carboxamide, a new antiviral agent. Antimicrob Agents Chemother 24: 353-361.
8. Snell NJC, (2001) Ribavirin - current status of a broad spectrum antiviral agent. Expert Opin Pharmacother 2: 1317-1324.
9. Murphy ME, Kariwa H, Mizutani T, Tanabe H, Yoshimatsu K, et al. (2001) Characterization of in vitro and in vivo antiviral activity of Lactoferrin and ribavirin upon Hantavirus. J Vet Med Sci 63: 637-645.
10. Severson WE, Schmaljohn CS, Javadian A, Jonsson CB, (2003) Ribavirin causes error catastrophe during Hantaan virus replication. J Virol 77: 481-488.
11. Sun Y, Chung DH, Chu YK, Jonsson CB, Parker WB, (2007) Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5′-triphosphate, not with inhibition of IMP dehydrogenase. Antimicrob Agents Chemother 51: 84-88.
12. Huggins JW, Kim GR, Brand OM, McKee KY Jr, (1986) Ribavirin therapy for Hantaan virus infection in suckling mice. J Infect Dis 153: 489-497.
13. Huggins JW, Hsiang CM, Cosgriff TM, Guang MY, Smith JI, et al. (1991) Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 164: 1119-1127.
14. Rusnak JM, Byrne WR, Chung KN, Gibbs PH, Kim TT, et al. (2009) Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea. Antiviral Res 81: 68-76.
15. Jonsson CB, Hooper J, Mertz G, (2008) Treatment of hantavirus pulmonary syndrome. Antiviral Res 78: 162-169.
16. Medina RA, Mirowsky-Garcia K, Hutt J, Hjelle B, (2007) Ribavirin, human convalescent plasma and anti-beta3 integrin antibody inhibit infection by Sin Nombre virus in the deer mouse model. J Gen Virol 88: 493-505.
17. Chapman LE, Mertz GJ, Peters CJ, Jolson HM, Khan AS, et al. (1999) Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin study group. Antivir Ther 4: 211-219.
18. Mertz GJ, Miedzinski L, Goade D, Pavia AT, Hjelle B, et al. (2004) Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis 39: 1307-1313.
19. Hooper JW, Larsen T, Custer DM, Schmaljohn CS, (2001) A lethal disease model for hantavirus pulmonary syndrome. Virology 289: 6-14.
20. Wahl-Jensen V, Chapman J, Asher L, Fisher R, Zimmerman M, et al. (2007) Temporal analysis of Andes virus and Sin Nombre virus infections of Syrian hamsters. J Virol 81: 7449-7462.
21. Meissner JD, Rowe JE, Borucki MK, Joer SC St, (2002) Complete nucleotide sequence of a Chilean hantavirus. Virus Res 89: 131-143.
22. Safronetz D, Hegde NR, Ebihara H, Denton M, Kobinger GP, et al. (2009) Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with Andes virus. J Virol 83: 7285-7295.
23. Zivcec M, Safronetz D, Haddock E, Feldmann H, Ebihara H, (2011) Validation of assays to monitor immune responses in Syrian hamsters (Mesocricetus auratus). J Immunol Method 368: 24-35.
24. Enria DA, Briggiler AM, Pini N, Levis S, (2001) Clinical manifestations of New World hantaviruses. Curr Top Microbiol Immunol 256: 117-134.
25. Feldmann H, Sanchez A, Morzunov S, Spiropoulou CF, Rollin PE, et al. (1993) Utilization of autopsy RNA for the synthesis of the nucleocapsid antigen of a newly recognized virus associated with hantavirus pulmonary syndrome. Virus Res 30: 351-367.
26. Dietl CA, Wernly JA, Pett SB, Yassin SF, Sterling JP, et al. (2008) Extracorporeal membrane oxygenation support improves survival of patients with severe Hantavirus cardiopulmonary syndrome. J Thorac Cardiovasc Surg 135: 579-584.
27. Olschlager S, Neyts J, Gunther S, (2011) Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus. Antiviral Res doi10.1016/j.antiviral.2011.05.006.
28. Bossi P, Tegnell A, Baka A, Van Loock F, Hendriks J, et al. (2004) Bichat guidelines for the clinical management of haemorrhagic fever viruses and bioterrorism-related haemorrhagic fever viruses. Euro Surveill 9: E11-2.
29. Chung DH, Sun Y, Parker WB, Arterburn JB, Bartolucci A, et al. (2007) Ribavirin reveals a lethal threshold of allowable mutation frequency for Hantaan virus. J Virol 81: 11722-11729.
30. Borges AA, Campos GM, Moreli ML, Souza RLM, Saggioro FP, et al. (2008) Role of mixed Th1 and Th2 serum cytokines on pathogenesis and prognosis of hantavirus pulmonary syndrome. Microbes Infect 10: 1150-1157.
31. Rusnak JM, Kortepeter MG, Aldis J, Boudreau E, (2004) Experience in the medical management of potential laboratory exposures to agents of bioterrorism on the basis of risk assessment at the United States army medical research institute of infectious diseases (USAMRIID). J Occup Environ Med 46: 801-811.